Statute Details
- Title: Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016
- Act Code: MA1975-S336-2016
- Legislation Type: Subsidiary legislation (SL)
- Enacting Act: Medicines Act (Cap. 176)
- Authorising Provisions: Sections 18, 34, 44 and 74 of the Medicines Act
- Commencement: 1 November 2016
- Status: Current version as at 27 Mar 2026
- Key Parts: Part 1 (General); Part 2 (Exemptions for clinical research materials); Part 3 (Manufacture, assembly and import); Part 4 (Supplies); Part 5 (Duties, records, reporting); Part 6 (Miscellaneous)
- Key Sections (from extract): Section 2 (Definitions); Sections 3–14 (core operational duties); First Schedule (Excluded medicinal products); Second Schedule (Labelling requirements)
- Notable Cross-References: Healthcare Services Act 2020; Human Biomedical Research Act 2015; Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 also interacts with clinical trial frameworks under other regulations
What Is This Legislation About?
The Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 (“CRM Regulations”) create a specialised regulatory pathway for medicinal products that are used in human clinical research. In practical terms, the Regulations recognise that medicines used in research—whether investigational products being tested, placebos, or other materials used under a research protocol—often need to be manufactured, imported, supplied, labelled, tracked, and monitored differently from ordinary commercial medicines.
The Regulations sit within Singapore’s broader medicines and research compliance architecture. They operate under the Medicines Act (Cap. 176) and provide exemptions and operational requirements so that clinical research can proceed while maintaining patient safety and regulatory oversight. The CRM Regulations focus on the lifecycle of “clinical research materials” (CRMs): how they are made, assembled, imported, supplied, handled, labelled, recorded, and reported when adverse events occur or when a recall is necessary.
Importantly, the Regulations do not treat all medicinal products used in research identically. They distinguish between materials that are part of the research intervention (investigational CRMs) and other materials used for research purposes (auxiliary CRMs), and they exclude certain medicinal products through the First Schedule. The labelling requirements in the Second Schedule ensure that CRMs can be identified and used correctly at trial sites.
What Are the Key Provisions?
1. Definitions and regulatory scope (Section 2)
The starting point for legal analysis is the definition of “clinical research material”. A “clinical research material” means any medicinal product or placebo that is not specified in the First Schedule, and that is manufactured, assembled, imported or supplied for the purpose of being used in clinical research by way of administration to a subject in accordance with the protocol. This definition is crucial because it determines when the Regulations apply and when exemptions from the Medicines Act may be available.
The Regulations also define “investigational CRM” (the material to be tested or used as a reference) and “auxiliary CRM” (used for the needs of clinical research but not as the material to be tested or used as a reference). The definition of “clinical research” is broad: it covers any research involving human beings, whether or not it is a regulated clinical trial. This breadth means that the CRM Regulations can apply even outside the narrow universe of trials that are formally “regulated clinical trials” under the clinical trial regulations.
2. Exemptions from the Medicines Act (Section 3)
Part 2 provides “Exemptions for clinical research materials”. While the extract does not reproduce the text of Section 3, the structure indicates that the Regulations carve out clinical research materials from certain general requirements under the Medicines Act. For practitioners, the key point is that compliance is not “business as usual”: the CRM Regulations create a tailored compliance regime. When advising sponsors, contract research organisations, manufacturers, or importers, counsel should map which Medicines Act obligations are displaced and which CRM-specific duties replace them.
3. Manufacture, assembly and import (Section 4)
Part 3 governs the manufacture, assembly and import of CRMs. The legal effect is to impose conditions on entities that produce or bring CRMs into Singapore for research use. This is a high-risk area because CRMs may be unlicensed, investigational, or not intended for general market supply. The Regulations therefore require that manufacture, assembly and import occur under a framework consistent with safe handling and traceability.
4. Supply and labelling (Sections 5 and 6; Second Schedule)
Part 4 addresses supply. Section 5 focuses on “Supply only as clinical research material”, which signals that CRMs must be supplied for research purposes and not diverted into ordinary channels. Section 6 requires “Supply of clinical research material properly labelled”, linking directly to the Second Schedule labelling requirements.
From a practitioner’s perspective, labelling is often the first point of failure in audits. The Regulations’ labelling requirements are designed to ensure that trial sites can identify the CRM, understand its intended use, and handle it appropriately. Where CRMs are supplied to multiple trial sites or across time, correct labelling also supports inventory control and reduces the risk of mix-ups between investigational products, placebos, and auxiliary materials.
5. Duties relating to dealing, records, and reporting (Part 5)
Part 5 is the operational backbone of the Regulations. Division 1 addresses “Use and disposal, etc., of clinical research materials” and includes Section 7 (“Dealing with clinical research materials”). This provision governs how CRMs may be handled during the research lifecycle—covering matters such as appropriate use in accordance with the protocol and safe disposal practices.
Division 2 imposes detailed record-keeping duties. Sections 8 to 11 require records of manufacture, receipt and supply, and dealings with CRMs, and they specify the “production of and time for keeping of records”. This is critical for regulatory defensibility: if an adverse event occurs, the Authority can trace the chain of custody and determine what happened, when, and by whom.
Division 3 requires reporting to the Authority. Section 12 mandates notifications of “unexpected serious adverse drug reactions”. Section 13 provides for “Recall of clinical research material”. Together, these provisions align CRM handling with pharmacovigilance principles: unexpected serious adverse reactions must be escalated promptly, and where necessary, CRMs must be recalled to protect subjects and prevent further exposure.
6. Offences (Section 14)
Part 6 includes offences. While the extract does not set out penalties, the presence of an offences section indicates that breaches of the CRM Regulations—such as improper supply, inadequate labelling, failure to keep records, or failure to report adverse reactions—carry legal consequences. For counsel, this means compliance is not merely contractual; it is enforceable regulatory law.
How Is This Legislation Structured?
The CRM Regulations are organised into six Parts:
Part 1 (General) contains the citation/commencement provision (Section 1) and definitions (Section 2). Definitions are especially important because they determine whether a product is a “clinical research material” and whether the research is “clinical research” for the Regulations’ purposes.
Part 2 (Exemptions for clinical research materials) contains Section 3, which sets out exemptions from the Medicines Act for CRMs. This Part is the gateway to understanding how the general medicines regime is modified for research use.
Part 3 (Manufacture, assembly and import) contains Section 4, setting requirements for entities that produce or import CRMs.
Part 4 (Supplies, etc.) contains Sections 5 and 6, focusing on supply limitations and proper labelling.
Part 5 (Duties relating to clinical research materials) is the most substantive compliance section. It is divided into (i) dealing/use/disposal (Division 1, including Section 7), (ii) record-keeping (Division 2, Sections 8–11), and (iii) reports to the Authority (Division 3, Sections 12–13).
Part 6 (Miscellaneous) contains Section 14 on offences.
Two Schedules support the operational requirements: First Schedule lists excluded medicinal products (i.e., products not treated as CRMs under the Regulations), and Second Schedule sets out labelling requirements.
Who Does This Legislation Apply To?
The CRM Regulations apply to persons involved in the manufacture, assembly, import, supply, handling, record-keeping, and reporting of clinical research materials. In practice, this includes sponsors, manufacturers, importers, distributors/suppliers, and trial-site personnel who deal with CRMs under a protocol.
The Regulations also incorporate definitions linked to Singapore’s healthcare and research governance framework. For example, the definition of “approved permanent premises”, “approved conveyance”, and “permanent premises” refers to the Healthcare Services Act 2020. The definition of “healthcare service licensee” similarly draws on the Healthcare Services Act 2020. The definition of “institutional review board” is tied to the Human Biomedical Research Act 2015. These cross-references mean that compliance advice must be coordinated across multiple statutes and regulatory regimes, particularly where trial sites and sponsors operate through licensed healthcare services or institutional review boards.
Why Is This Legislation Important?
The CRM Regulations are important because they operationalise the balance between enabling clinical research and protecting subjects. Clinical research often involves products that are not yet authorised for general sale. Without a tailored regulatory framework, it would be difficult to manage risks such as product quality, traceability, and pharmacovigilance.
For practitioners, the most significant practical impact lies in the compliance obligations that are likely to be audited or scrutinised after an incident. Record-keeping duties (Sections 8–11) and reporting obligations (Section 12) are particularly consequential. If an unexpected serious adverse drug reaction occurs, the sponsor and relevant supply chain actors must be able to demonstrate what CRMs were used, where they came from, and how they were handled. Similarly, recall powers (Section 13) require readiness to retrieve and account for CRMs quickly.
Finally, the labelling requirements (Section 6 and the Second Schedule) are a recurring compliance risk. Incorrect labelling can lead to protocol deviations, dosing errors, or inability to distinguish investigational products from placebos and auxiliary materials. Because the Regulations impose legal duties, counsel should ensure that labelling workflows, translation/formatting, and version control are contractually and operationally robust.
Related Legislation
- Medicines Act (Cap. 176)
- Healthcare Services Act 2020
- Human Biomedical Research Act 2015
- Medicines (Clinical Trials) Regulations 2016
- Health Products (Clinical Trials) Regulations 2016
- Healthcare Services (Outpatient Medical Service) Regulations 2023 (for defined terms such as “remote service kiosk”)
Source Documents
This article provides an overview of the Medicines (Medicinal Products as Clinical Research Materials) Regulations 2016 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.